ID   A549 EML4-ALK
AC   CVCL_JK07
SY   EML4-ALK Fusion-A549 Isogenic Cell Line
DR   ATCC; CCL-185IG
DR   cancercelllines; CVCL_JK07
DR   Wikidata; Q54606944
RX   CelloPub=CLPUB00395;
CC   Population: Caucasian.
CC   Characteristics: An EML4-ALK4 fusion was generated by CRISPR/Cas9.
CC   Characteristics: More sensitive to the ALK inhibitor crizotinib when compared to the parental cell line. Can be a useful model to study tyrosine kinase signaling pathway and to screen ALK inhibitors.
CC   Doubling time: ~25 hours (ATCC=CCL-185IG).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): ATCC=CCL-185IG
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D5S818: 11
ST   D7S820: 8,11
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 14
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 15-05-17; Last updated: 02-05-24; Version: 11
//
RX   CelloPub=CLPUB00395;
RA   Enuameh M.S., Volpe L.-A., Jackson M., Foulke J., Chen L.-P.,
RA   Shapiro B.A., Tian F.;
RT   "The generation of an EML4-ALK fusion NSCLC isogenic cell line relevant
RT   for drug discovery and development.";
RL   (In) ATCC application note 25; pp.1-4; ATCC; Manassas (2016).
//